In this Monographic issue on Oligonucleotides & Peptides we have foreseen a Panel discussion on Oligonucleotides involving companies in the supply chain. In the next few pages the reader will have an update on improvements obtained in the delivery pathway, on the impact stereochemically pure oligonucleotides are having in the field, the hurdles that need to be overcome to make oligonucleotides a viable strategy for delivering personalized medicine, how regulatory guidance could help their development and finally the areas where further technological advances may be needed (i.e. analytical tools).

The following Players have joined this initiative:




Johannes Müller
CEO and CMO
Berlin Cures

< ... ... ...